You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Untreated Diffuse Large B-Cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)

Not yet recruiting
  • Large B-cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Homburg, Saarland, Germany
    Saarland University Medical Center
Apr 19, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

DLBCL Trial in Cleveland (Loncastuximab tesirine, Prednisone, Rituximab)

Withdrawn
  • Diffuse Large B-Cell Lymphoma
  • Loncastuximab tesirine
  • +5 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center
Mar 15, 2022

Lymphoma Trial in Worldwide (Glofitamab, Tocilizumab, Doxorubicin)

Recruiting
  • Lymphoma
  • Duarte, California
  • +13 more
Aug 18, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Orelabrutinib in Combination With Standard Treatment Regimen for

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Aug 23, 2023

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

DLBCL, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 12, 2022

Diffuse Large B Cell Lymphoma Trial in Colchester, Canterbury, Nottingham (R-CHOP, R-CHOP + acalabrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +32 more
Oct 25, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Diffuse Large B-cell Lymphoma Trial in United States (Loncastuximab Tesirine, Rituximab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Reno, Nevada
  • +4 more
Jul 1, 2022

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Non-Hodgkin's Lymphoma Trial in New York (Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin,

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Etoposide, carboplatin, ifosfamide
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 23, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria, Germany (Glofitamab, Rituximab, Obinutuzumab)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Linz, Austria
  • +17 more
Mar 22, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Mosunetuzumab Intravenous (IV)
  • +3 more
  • Birmingham, Alabama
  • +52 more
Aug 19, 2022

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse Trial run by the NCI (Rituximab, Filgrastim, EPOCH)

Active, not recruiting
Has Results
  • Lymphoma, AIDS-related
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jul 21, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Durvalumab, Rituximab, Doxorubicin)

Completed
Has Results
  • Lymphoma, Large B-Cell, Diffuse
  • Gilbert, Arizona
  • +18 more
Aug 19, 2022

AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell

Completed
Has Results
  • AIDS-related Diffuse Large Cell Lymphoma
  • +8 more
  • Eldoret, Kenya
  • +1 more
Sep 12, 2022

Recruiting Trial in Linyi (H02+CHOP, Rituxan +CHOP)

Recruiting
  • Recruiting
  • Linyi, Shandong, China
    Shandong New Time Pharmaceutical Co., LTD
Sep 7, 2021

DLBCL Trial in Chicago (Metformin, Rituximab, Cyclophosphamide)

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma
  • Chicago, Illinois
    Rush University Medical Center
Aug 24, 2021

Lymphoma, Large B-Cell, Diffuse Trial in China (Rituximab IV, Rituximab SC, Cyclophosphamide)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab IV
  • +7 more
  • Beijing, China
  • +9 more
Apr 6, 2022

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Venetoclax, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • New York, New York
  • +19 more
Aug 17, 2022